Weight-loss drug drives Eli Lilly to boost 2024 gross sales forecast via $2 billion
Through Bhanvi Satija and Patrick Wingrove(Reuters) -Explosive call for and larger production capability for Eli Lilly’s weight-loss drug Zepbound drove the corporate to boost its annual gross sales forecast via $2 billion
